BNP Paribas Financial Markets Has $29.48 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BNP Paribas Financial Markets boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,337,470 shares of the company's stock after buying an additional 168,699 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.12% of Teva Pharmaceutical Industries worth $29,478,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Oarsman Capital Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $44,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $66,000. Finally, IFP Advisors Inc raised its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded down $0.48 during trading hours on Tuesday, hitting $17.48. The company had a trading volume of 13,690,780 shares, compared to its average volume of 10,080,678. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The business has a fifty day simple moving average of $15.22 and a 200-day simple moving average of $17.44. The firm has a market cap of $19.82 billion, a P/E ratio of -12.06, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the prior year, the firm posted $0.48 earnings per share. The company's revenue was up 1.9% on a year-over-year basis. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

TEVA has been the topic of several research reports. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $21.00 to $23.00 in a research note on Monday. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $24.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.